Skip to main content
. Author manuscript; available in PMC: 2018 May 9.
Published in final edited form as: N Engl J Med. 2017 Nov 9;377(19):1836–1846. doi: 10.1056/NEJMoa1701830

Figure 3. Association between Pathological Nodal Status and the Risk of Distant Recurrence during Years 5 to 20 of the Study, According to Tumor Stage.

Figure 3

Shown are the data for 62,923 women with ER-positive disease who were enrolled in 88 trials of breast-cancer therapy and who initiated therapy either at year 0 or within the first 5 years, according to whether they had T1 disease (Panel A) or T2 disease (Panel B). All the women were scheduled to receive 5 years of endocrine therapy and were event-free and still being followed at year 5. The I bars indicate 95% confidence intervals. The dashed lines indicate that the event rate is for the whole 5-year period, rather than for individual years, as is otherwise shown. Data for the number of events and annual rate begin at 5 years, since the analysis of the risk of distant recurrence starts at year 5.